Unibest 优贝德
← Back to patent-cliff list

图卡替尼

Tier C — Watch / trade

Tucatinib · all drugs expiring in 2030 →

Array Biopharma
Originator
2020
First approval
2030
Expiry (public)
$0.48B ▲
Peak sales
化学药
Type

TargetsHER2

BrandTukysa

Indications (approved)乳腺癌、结直肠癌

Regional status

US
批准上市
2020-04-17
EU
批准上市
2021-02-11
China
临床三期
2019-10-02
Japan
批准上市
2026-02-19

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield /
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
IRBIN-00117420-30-3Available2-amino-5-nitrobenzonitrile
IRBIN-0021203904-18-0Available(E)-N'-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide
IRBIN-0032131230-48-1Available(E)-N'-(4-amino-2-cyanophenyl)-N,N-dimethylformimidamide
IRBIN-004124-68-5Available2-amino-2-methylpropan-1-ol
IRBIN-0051429755-57-6Available(E)-N'-(2-cyano-4-(3-(1-hydroxy-2-methylpropan-2-yl)thioureido)phenyl)-N,N-dimethylformimidamide
IRBIN-006937263-71-3Available7-(4-(l2-azaneyl)-2-methylphenoxy)-[1,2,4]triazolo[1,5-a]pyridine
IRBIN-0071429755-58-7Available1-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea
IRBIN-008864244-98-4Available4-(2-methyl-4-nitrophenoxy)pyridin-2-amine
IRBIN-009-(E)-N,N-dimethyl-N'-(4-(2-methyl-4-nitrophenoxy)pyridin-2-yl)formimidamide
IRBIN-010937263-44-0Available7-(2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine
Irbinitinib937263-43-9AvailableN4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine

Frequently asked questions

What are the approved indications of Tucatinib?

Approved indications include: 乳腺癌, 结直肠癌.

When does the Tucatinib patent expire?

Based on public sources, the Tucatinib patent expires in 2030.

How many synthesis routes are recorded for Tucatinib?

1 synthesis routes are recorded; the shortest is 8 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Tucatinib intermediates?

10 intermediate CAS of Tucatinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Tucatinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24